RÉSUMÉ
Human herpesvirus 6A (HHV-6A) and 6B (HHV-6B) are two closely related viruses that can infect cells of the central nervous system (CNS). The similarities between these viruses have made it difficult to separate them on serological level. The broad term HHV-6 remains when referring to studies where the two species were not distinguished, and as such, the seroprevalence is over 90% in the adult population. HHV-6B has been detected in up to 100% of infants with the primary infection roseola infantum, but less is known about the primary infection of HHV-6A. Both viruses are neurotropic and have capacity to establish lifelong latency in cells of the central nervous system, with potential to reactivate and cause complications later in life. HHV-6A infection has been associated with an increased risk of multiple sclerosis (MS), whereas HHV-6B is indicated to be involved in pathogenesis of epilepsy. These two associations show how neurological diseases might be caused by viral infections, but as suggested here, through completely different molecular mechanisms, in an autoimmune disease, such as MS, by triggering an overreaction of the immune system and in epilepsy by hampering internal cellular functions when the immune system fails to eliminate the virus. Understanding the viral mechanisms of primary infection and reactivation and their spectrum of associated symptoms will aid our ability to diagnose, treat and prevent these severe and chronic diseases. This review explores the role of HHV-6A and HHV-6B specifically in MS and epilepsy, the evidence to date and the future directions of this field.
Sujet(s)
Système nerveux central/virologie , Épilepsie/virologie , Exanthème subit/virologie , Herpèsvirus humain de type 6/physiologie , Sclérose en plaques/virologie , Animaux , Auto-immunité , Épigenèse génétique , Épilepsie/immunologie , Exanthème subit/immunologie , Humains , Sclérose en plaques/immunologie , RisqueRÉSUMÉ
Human herpesvirus 6A (HHV-6A) is a member of the genus Roseolovirus and the subfamily Betaherpesvirinae. It is similar to and human cytomegalovirus (HCMV). HHV-6A encodes a 41 kDa nuclear phosphoprotein, U27, which acts as a processivity factor in the replication of the viral DNA. HHV-6A U27 has 43% amino acid sequence homology with HCMV UL44, which is important for DNA replication. A previous study on HHV-6A U27 revealed that it greatly increases the in vitro DNA synthesis activity of HHV-6A DNA polymerase. However, the role of U27 during the HHV-6A virus replication process remains unclear. In this study, we constructed a U27-deficient HHV-6A mutant (HHV-6ABACU27mut) with a frameshift insertion at the U27 gene using an HHV-6A bacterial artificial chromosome (BAC) system. Viral reconstitution from the mutant BAC DNA was not detected, in contrast to the wild type and the revertant from the U27 mutant. This suggests that U27 plays a critical role in the life cycle of HHV-6A.
Sujet(s)
Herpèsvirus humain de type 6/génétique , Protéines virales/génétique , Réplication virale/génétique , Lignée cellulaire , Réplication de l'ADN/génétique , ADN viral/génétique , Exanthème subit/virologie , Fièvre/virologie , Mutation avec décalage du cadre de lecture/génétique , Génome viral/génétique , Cellules HEK293 , HumainsRÉSUMÉ
Primary infection of human herpesvirus 6B (HHV-6B) occurs in infants after the decline of maternal immunity and causes exanthema subitum accompanied by a high fever, and it occasionally develops into encephalitis resulting in neurological sequelae. There is no effective prophylaxis for HHV-6B, and its development is urgently needed. The glycoprotein complex gH/gL/gQ1/gQ2 (called 'tetramer of HHV-6B') on the virion surface is a viral ligand for its cellular receptor human CD134, and their interaction is thus essential for virus entry into the cells. Herein we examined the potency of the tetramer as a vaccine candidate against HHV-6B. We designed a soluble form of the tetramer by replacing the transmembrane domain of gH with a cleavable tag, and the tetramer was expressed by a mammalian cell expression system. The expressed recombinant tetramer is capable of binding to hCD134. The tetramer was purified to homogeneity and then administered to mice with aluminum hydrogel adjuvant and/or CpG oligodeoxynucleotide adjuvant. After several immunizations, humoral and cellular immunity for HHV-6B was induced in the mice. These results suggest that the tetramer together with an adjuvant could be a promising candidate HHV-6B vaccine.
Sujet(s)
Exanthème subit/immunologie , Vaccins contre les herpèsvirus/immunologie , Protéines de l'enveloppe virale/immunologie , Adjuvants immunologiques/pharmacologie , Animaux , Exanthème subit/virologie , Herpèsvirus humain de type 6 , Humains , Souris , Souris de lignée BALB CRÉSUMÉ
During local small measles outbreak in Japan, 3 adolescents with febrile skin rash suspected as having measles were diagnosed with primary human herpesvirus (HHV)-7 infection. Primary HHV-7 infection can cause exanthem subitum in not only young children but also adolescents. HHV-7 should be considered as a possible causative agent for adolescent febrile skin rash during the measles outbreak.
Sujet(s)
Anticorps antiviraux/sang , Épidémies de maladies/statistiques et données numériques , Exanthème subit/diagnostic , Rougeole/épidémiologie , Infections à roséolovirus/diagnostic , Adolescent , Exanthème subit/virologie , Femelle , Fièvre/virologie , Herpèsvirus humain de type 7/isolement et purification , Herpèsvirus humain de type 7/pathogénicité , Humains , Japon/épidémiologie , MâleRÉSUMÉ
HHV-6A and HHV-6B are ubiquitous human betaherpesviruses sharing more than 80% homology. HHV-6B is the most common cause of encephalitis in transplant patients and its primary infection may cause the exanthema subitum and febrile seizures in infants. HHV-6A and HHV-6B are able to infect several immune cell types such as T cells, monocytes and dendritic cells (DCs). In this study we found that HHV-6 B derived from patients affected by exanthema subitum impaired monocyte differentiation into DCs, as the infected cells acquired less CD1a DC marker and retained more CD14 monocyte marker. In agreement with the previous finding that HHV-6B dysregulated autophagy and induced endoplasmic reticulum (ER) stress in cells in which it replicated, here we found that these effects occurred also in differentiating monocytes and that ER stress relief, by using the chemical chaperone sodium 4-phenylbutirate (PBA), partially restored DC formation. This suggests that the induction of ER stress, likely exacerbated by autophagy inhibition, could contribute to the immune suppression induced by HHV-6B derived from exanthema subitem patients.
Sujet(s)
Autophagie , Différenciation cellulaire , Cellules dendritiques/physiologie , Stress du réticulum endoplasmique , Herpèsvirus humain de type 6/physiologie , Monocytes/anatomopathologie , Monocytes/virologie , Survie cellulaire , Cellules cultivées , Cellules dendritiques/virologie , Exanthème subit/virologie , HumainsRÉSUMÉ
An immunocompetent toddler came to medication attention with gastroenteritis, complicated by encephalopathy and hepatitis. Multiplexed testing using a polymerase chain reaction meningitis panel was positive for human herpesvirus 6 (HHV-6). Clinical correlation, quantitative HHV-6 polymerase chain reaction, and metagenomic next-generation sequencing supported a likely diagnosis of primary HHV-6B infection.
Sujet(s)
Encéphalopathies/virologie , Exanthème subit/virologie , Gastroentérite/virologie , Hépatite/virologie , Herpèsvirus humain de type 6/isolement et purification , Réaction de polymérisation en chaine multiplex , Herpèsvirus humain de type 6/génétique , Humains , Immunocompétence , Nourrisson , Mâle , Appréciation des risquesRÉSUMÉ
BACKGROUND AND OBJECTIVE: Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis that can be limited to the skin but may also affect other organs. Often, its cause is unknown. LCV has previously been reported to occur with the reactivation of human herpesvirus 6 (HHV-6). Here, we report a second instance of HHV-6 reactivation in a 43-year-old woman with idiopathic cutaneous LCV. CASE DESCRIPTION: In this case, the patient was immunocompetent, and testing revealed that she had inherited chromosomally integrated human herpesvirus 6 variant A (iciHHV6-A) with a parallel skin infection of HHV-6B. The integrated ciHHV-6A strain was found to be transcriptionally active in the blood, while HHV-6B late antigen was detected in a skin biopsy. The patient's rash was not accompanied by fever nor systemic symptoms and resolved over four weeks without any therapeutic intervention. CONCLUSION: In light of the transcriptional activity documented in our case, further examination of a possible role for HHV-6 in the etiology of LCV is warranted.
Sujet(s)
Exanthème subit/complications , Herpèsvirus humain de type 6 , Immunocompétence , Vascularite leucocytoclasique cutanée/complications , Adulte , Co-infection/complications , Co-infection/diagnostic , Co-infection/immunologie , Co-infection/virologie , Exanthème subit/diagnostic , Exanthème subit/immunologie , Exanthème subit/virologie , Femelle , Herpèsvirus humain de type 6/classification , Herpèsvirus humain de type 6/isolement et purification , Humains , Infections à roséolovirus/complications , Infections à roséolovirus/immunologie , Infections à roséolovirus/virologie , Vascularite leucocytoclasique cutanée/diagnostic , Vascularite leucocytoclasique cutanée/immunologie , Vascularite leucocytoclasique cutanée/virologieRÉSUMÉ
BACKGROUND: Human herpesvirus 6B (HHV-6B) is the causative agent of Roseola infantum, and has also been suggested to play a role in the pathogenesis of febrile seizures in young children, a percentage of whom go on to develop febrile status epilepticus (FSE), but the existing data is conflicting and inconclusive. HHV-6A is a distinct species, rarely detected in most parts of the world, but prior studies suggest a higher prevalence in febrile African children. We describe a case-control study comparing the frequency of HHV-6A and/or HHV-6B infections in children with febrile seizures (including FSE) and a control group of febrile children without seizures. METHODS: We recruited children aged 6 to 60 months admitted with a febrile illness with (cases) or without (controls) seizures presenting within 48 hours of commencement of fever. Three milliliters of whole blood was centrifuged and plasma stored at -80°C for pooled screening for HHV-6B and HHV-6A by Taqman real-time polymerase chain reaction. RESULTS: 102 cases and 95 controls were recruited. The prevalence of HHV-6B DNA detection did not differ significantly between cases (5.8% (6/102)) and controls (10.5% (10/95)) but HHV-6B infection was associated with FSE (OR, 15; 95% CI, [1.99-120]; P= 0.009). HHV-6A was not detected. CONCLUSION: Prevalence of HHV-6B was similar among cases and controls. Within the FS group, HHV-6B infection was associated with FSE, suggesting HHV-6B infections could play a role in the pathogenesis of FSE.
Sujet(s)
Exanthème subit/complications , Exanthème subit/anatomopathologie , Herpèsvirus humain de type 6/isolement et purification , Crises convulsives fébriles/épidémiologie , État de mal épileptique/épidémiologie , Études cas-témoins , Enfant d'âge préscolaire , Exanthème subit/virologie , Femelle , Herpèsvirus humain de type 6/génétique , Hôpitaux , Humains , Nourrisson , Mâle , Prévalence , Réaction de polymérisation en chaine en temps réel , Zambie/épidémiologieRÉSUMÉ
The amounts of the DNAs of human herpesviruses-6 (HHV-6) and -7 (HHV-7) in saliva samples were monitored during the acute and convalescent phases of exanthem subitum (ES) to elucidate the kinetics of virus shedding after ES. A total of 247 saliva samples were collected from 17 children (5 males and 12 females: 8-31 months old at onset). The monitoring period ranged from 152 to 721 days after onset, and in 15 children it was longer than 1 year. Among the 17 cases, 16 were attributed to HHV-6B, while a single case was attributed to HHV-7. Detection rates and average amounts of HHV-6 DNA in saliva samples after ES attributed to HHV-6B were low in the acute phase, increased to the maximum in the convalescent phase at 3-7 months, and then decreased. In addition, to investigate the source of infection, saliva samples from the older siblings (age 3-9 years) and parents of ES patients and children with a history of ES were also examined. The detection rate of HHV-6 DNA in saliva samples from 3- to 9-year-old children was significantly higher than the rate in adult saliva samples. Taken together, these findings suggest that the saliva of children in the convalescent phase of ES might be a more likely source of HHV-6 infection than that of adults. J. Med. Virol. 89:696-702, 2017. © 2016 Wiley Periodicals, Inc.
Sujet(s)
ADN viral/analyse , Exanthème subit/virologie , Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 7/génétique , Salive/virologie , Excrétion virale , Adulte , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Mâle , Facteurs tempsRÉSUMÉ
Primary infection with human herpesvirus-6 (HHV-6), is followed by its lifelong persistence in the host. Most T-cell responses to HHV-6 have been characterized using peripheral blood from healthy adults; however, the role of HHV-6 infection in immune modulation has not been elucidated for some diseases. Therefore, in this study the immune response to HHV-6 infection in patients with B-acute lymphoblastic leukemia (B-ALL) was analyzed. HHV-6 load was quantified in blood samples taken at the time of diagnosis of leukemia and on remission. The same concentrations of anti- and pro-inflammatory cytokines (IL-4, IL-1, IL-6, IL-8, IL-12p70, IL-17a, TNF-α and IFN-γ) were detected in plasma samples from 20 patients with and 20 without detectable HHV-6 virus loads in blood. Characterization of T-cell responses to HHV-6 showed low specific T-cells frequencies of 2.08% and 1.46% in patients with and without detectable viral loads, respectively. IFN-γ-producing T cells were detected in 0.03%-0.23% and in 0%-0.2% of CD4+T cells, respectively. Strong production of IL-6 was detected in medium supernatants of challenged T-cells whatever the HHV-6 status of the patients (973.51 ± 210.06 versus 825.70 ± 210.81 pg/mL). However, concentrations of TNF-α and IFN-γ were low. Thus, no association between plasma concentrations of cytokines and detection of HHV-6 in blood was identified, suggesting that HHV-6 is not strongly associated with development of B-ALL. The low viral loads detected may correspond with latently infected cells. Alternatively, HHV-6B specific immune responses may be below the detection threshold of the assays used.
Sujet(s)
Cytokines/biosynthèse , Herpèsvirus humain de type 6/immunologie , Immunité cellulaire , Leucémie-lymphome lymphoblastique à précurseurs B et T/immunologie , Leucémie-lymphome lymphoblastique à précurseurs B et T/métabolisme , Adulte , Moelle osseuse/anatomopathologie , Lignée cellulaire , Cytokines/sang , ADN viral , Exanthème subit/immunologie , Exanthème subit/métabolisme , Exanthème subit/virologie , Femelle , Humains , Immunophénotypage , Agranulocytes/immunologie , Agranulocytes/métabolisme , Numération des lymphocytes , Mâle , Leucémie-lymphome lymphoblastique à précurseurs B et T/diagnostic , Leucémie-lymphome lymphoblastique à précurseurs B et T/virologie , Sous-populations de lymphocytes T/immunologie , Sous-populations de lymphocytes T/métabolisme , Sous-populations de lymphocytes T/virologie , Charge virale , Jeune adulteRÉSUMÉ
Human herpesvirus 6 (HHV-6) is increasingly recognized as a potentially life-threatening pathogen in allogeneic hematopoietic stem cell transplantation (alloSCT). We retrospectively evaluated 54 adult patients who developed positivity to HHV-6 after alloSCT. The median time from alloSCT to HHV-6 reactivation was 34 days. HHV-6 was present in plasma samples from 31 patients, in bone marrow (BM) of 9 patients, in bronchoalveolar lavage fluid and liver or gut biopsy specimens from 33 patients, and in cerebrospinal fluid of 7 patients. Twenty-nine patients developed acute graft-versus-host disease (GVHD), mainly grade III-IV, and 15 had concomitant cytomegalovirus reactivation. The median absolute CD3+ lymphocyte count was 207 cells/µL. We reported the following clinical manifestations: fever in 43 patients, skin rash in 22, hepatitis in 19, diarrhea in 24, encephalitis in 10, BM suppression in 18, and delayed engraftment in 11. Antiviral pharmacologic treatment was administered to 37 patients; nonetheless, the mortality rate was relatively high in this population (overall survival [OS] at 1 year, 38% ± 7%). A better OS was significantly associated with a CD3+ cell count ≥200/µL at the time of HHV-6 reactivation (P = .0002). OS was also positively affected by the absence of acute GVHD grade III-IV (P = .03) and by complete disease remission (P = .03), but was not significantly influenced by steroid administration, time after alloSCT, type of antiviral prophylaxis, plasma viral load, or organ involvement. Although HHV-6 detection typically occurred early after alloSCT, better T cell immune reconstitution seems to have the potential to improve clinical outcomes. Our findings provide new insight into the interplay between HHV-6 and the transplanted immune system.
Sujet(s)
Herpèsvirus humain de type 6/physiologie , Infections à roséolovirus/étiologie , Greffe haplo-identique/effets indésirables , Adulte , Sujet âgé , Antiviraux/usage thérapeutique , Cytomegalovirus , Exanthème subit/virologie , Femelle , Survie du greffon/immunologie , Maladie du greffon contre l'hôte/étiologie , Transplantation de cellules souches hématopoïétiques , Herpèsvirus humain de type 6/immunologie , Humains , Numération des lymphocytes , Mâle , Adulte d'âge moyen , Études rétrospectives , Stéroïdes/usage thérapeutique , Analyse de survie , Greffe haplo-identique/mortalité , Résultat thérapeutique , Activation virale , Maladies virales/traitement médicamenteux , Maladies virales/étiologie , Maladies virales/mortalité , Jeune adulteRÉSUMÉ
During the 1970s there was a gross loss of public confidence in infant diphtheria-tetanus-pertussis (DTP) vaccination in the UK. As well as febrile reactions and convulsions, permanent neurological damage was ascribed to the pertussis component of the vaccine, and those concerns resonated worldwide. The subsequent recognition of human herpes virus 6 (HHV-6) and 7 (HHV-7) as common sources of fever in infancy suggests that they were the main underlying cause of what was reported as DTP constitutional side-effects. With more precise data on the incidence of HHV-6/7 and other virus infections in early life it would be possible to model the concurrence of viral illnesses with routine immunizations. Adventitious viral infections may be the cause of side-effects ascribed to the numerous childhood immunizations now being given.
Sujet(s)
Bordetella pertussis/physiologie , Vaccin diphtérie-tétanos-coqueluche/effets indésirables , Exanthème subit/histoire , Herpèsvirus humain de type 6/physiologie , Herpèsvirus humain de type 7/physiologie , Coqueluche/histoire , Exanthème subit/épidémiologie , Exanthème subit/virologie , Histoire du 20ème siècle , Royaume-Uni/épidémiologie , Coqueluche/épidémiologie , Coqueluche/microbiologieRÉSUMÉ
We present the case of a 62-year-old man treated with high-dose chemotherapy and consecutive autologous stem cell transplantation for mantle cell lymphoma, who developed high fever and a rash of the trunk and both axillae 10 days after stem cell transplantation.
Sujet(s)
Exanthème subit/étiologie , Exanthème subit/virologie , Herpèsvirus humain de type 6 , Immunosuppresseurs/effets indésirables , Transplantation de cellules souches/effets indésirables , Humains , Sujet immunodéprimé , Mâle , Adulte d'âge moyen , Activation virale/immunologieRÉSUMÉ
Roseola infantum, also known as exanthem subitum or sixth disease, is a generally benign febrile exanthem of infancy. It has a characteristic clinical course of high fever followed by the appearance of an exanthem upon defervescence. Febrile seizures are a frequent complication. Roseola is caused by infection with human herpesviruses 6 or 7 (HHV-6/7), which are acquired at a young age. Diagnosis is made by serology or by virus detection in body fluids and tissues. Treatment of roseola is supportive; recovery is usually complete with no significant sequelae. However, HHV-6/7 can reactivate in immunocompetent as well as immunocompromised individuals with severe systemic consequence.
Sujet(s)
Exanthème subit/virologie , Herpèsvirus humain de type 6 , Herpèsvirus humain de type 7 , Diagnostic différentiel , Fièvre/virologie , Humains , Crises épileptiques/virologieRÉSUMÉ
In order to determine whether mixed infections of human herpesvirus 6B (HHV-6B) occur in immunocompetent and immunocompromised individuals, we examined the copy numbers of telomeric repeat sequences (TRS) of clinical isolates. In clinical isolates obtained from patients with exanthem subitum caused by primary HHV-6B infection, PCR products with HHV-6B TRS ranging between 400 and 800 bp were amplified. PCR products of various sizes were amplified in four clinical isolates from drug-induced hypersensitivity syndrome (DIHS) patients and 15 isolates from hematopoietic stem cell transplant (HSCT) recipients with HHV-6B reactivation. Based on the sequence analysis of the PCR products, the copy numbers of TRS in DIHS and HSCT patients were between 42 and 82 and 22 and >90, respectively. For two of the HSCT recipients, HHV-6B TRS PCR products of different sizes were detected in several isolates from each patient, which suggests mixed HHV-6B infections. In two of the posttransplant HHV-6B encephalitis patients, the sizes of the TRS nested PCR products amplified from the reactivated virus detected in the central nervous system differed from those of the virus detected in initial isolates from peripheral blood mononuclear cells. Taken together, these results suggest that PCR analysis of TRS copy number is a reliable tool for the discrimination of HHV-6B clinical isolates. Additionally, mixed HHV-6B infections occurred in HSCT recipients, and in some cases, compartmentalization of the HHV-6B strains to the central nervous system versus the blood compartment occurred in posttransplant HHV-6B encephalitis patients.
Sujet(s)
Co-infection/virologie , Exanthème subit/virologie , Dosage génique , Herpèsvirus humain de type 6/génétique , Séquences répétées d'acides nucléiques , Adolescent , Adulte , Sujet âgé , Enfant , Enfant d'âge préscolaire , ADN viral/génétique , Femelle , Variation génétique , Herpèsvirus humain de type 6/classification , Humains , Nourrisson , Mâle , Adulte d'âge moyen , Réaction de polymérisation en chaîne , Jeune adulteRÉSUMÉ
Kawasaki Disease (KD) is acute, febrile, multisystem vasculitis of early childhood, the detailed mechanism of which is still unclear. Skin symptoms occur in KD, such as edema of the hands and feet with subsequent desquamation and redness at the inoculation site of bacillus Calmette-Guerin (BCG). The change at the BCG inoculation site has been considered as a specific feature of KD, although its mechanism is not fully understood. We present an 11-month-old boy who developed fever with redness of the BCG site due to infection with human herpes virus type 6 (HHV6). At the age of 3 months, the patient received BCG. His fever remitted 7 days after the onset of skin redness, with sequential desquamation at the BCG site and extremities, which is not a common feature of HHV6 infection that typically lasts for 3 days. The final diagnosis was exanthema subitum. Characteristically, the HHV6 infection in our patient appeared to be associated with the invigoration of the T cell system, as represented by the elevated serum levels of soluble interleukin-2 receptor (3,490 U/ml vs. normal range 145-519 U/ml). This patient clearly showed redness and crusting at the BCG inoculation site, suggesting that HHV6 infection might cause skin changes similar to those of KD via an unknown mechanism. In addition, we suggest that the activation of the T cell system may account for the skin lesions in KD, characterized by redness and subsequent crusting of the BCG inoculation site and desquamation of the extremities.
Sujet(s)
Vaccin BCG/effets indésirables , Érythème/étiologie , Exanthème subit/diagnostic , Herpèsvirus humain de type 6/pathogénicité , Maladie de Kawasaki/immunologie , Peau/immunologie , Sous-populations de lymphocytes T/immunologie , Anticorps antiviraux/sang , Spécificité des anticorps , Diagnostic différentiel , Érythème/immunologie , Érythème/virologie , Exanthème subit/sang , Exanthème subit/immunologie , Exanthème subit/virologie , Fièvre/étiologie , Herpèsvirus humain de type 6/immunologie , Humains , Immunoglobuline M/sang , Nourrisson , Activation des lymphocytes , Mâle , Maladie de Kawasaki/diagnostic , Récepteurs à l'interleukine-2/sang , Peau/anatomopathologie , VaccinationRÉSUMÉ
Two closely related and commonly found human herpesviruses HHV-6 A and HHV-6 B are classified into the sixth human herpes virus complex (HHV-6). Primary infection with HHV-6 often takes place in early childhood and it can be either asymptomatic or manifests itself as sixth disease (caused by HHV-6 B). HHV-6 remains present in a latent form in the body with the potential for virus reactivation. The article points out the phenomenon of chromosomal integration of HHV-6 (Ci-HHV-6) which is found in about 1% of the population and, unlike the commonly spread HHV-6 infection, has become hereditary, with its pathological potential in Ci-HHV-6 DNA carriers remaining unknown. Therefore, the focus on clinical consequences of Ci-HHV-6 is of high relevance to the therapeutic strategy for patients with high HHV-6 positivity in molecular biological tests.
Sujet(s)
Exanthème subit/virologie , Herpèsvirus humain de type 6/génétique , Intégration virale/génétique , État de porteur sain/virologie , Exanthème subit/diagnostic , Exanthème subit/génétique , Exanthème subit/thérapie , HumainsRÉSUMÉ
The monitoring of active human herpesvirus 6 (HHV-6) B infection is important for distinguishing between the reactivation and latent state of the virus. The aim of this present study is to develop a quantitative reverse transcription polymerase chain reaction (RT-PCR) assay for diagnosis of active viral infection. Primers and probes for in house quantitative RT-PCR methods were designed to detect the three kinetic classes of HHV-6B mRNAs (U90, U12, U100). Stored PBMCs samples collected from 10 patients with exanthem subitum (primary HHV-6B infection) and 15 hematopoietic stem cell transplant recipients with HHV-6B reactivation were used to evaluate reliability for testing clinical samples. Excellent linearity was obtained with high correlation efficiency between the diluted RNA (1-100 ng/reaction) and C(t) value of each gene transcript. The U90 and U12 gene transcripts were detected in all of the peripheral blood mononuclear cells (PBMCs) samples collected in acute period of primary HHV-6B infection. Only one convalescent PBMCs sample was positive for the U90 gene transcript. Additionally, the reliability of HHV-6B quantitative RT-PCRs for diagnosis of viral reactivation in hematopoietic transplant recipients was evaluated. Relative to virus culture, U90 quantitative RT-PCR demonstrated the highest assay sensitivity, specificity, positive predictive value, and negative predictive value. Thus, this method could be a rapid and lower cost alternative to virus culture, which is difficult to perform generally, for identifying active HHV-6B infection.